Lopez Santiago, Majid Samiya, Syed Rida, Rychtar Jan, Taylor Dewey
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, United States of America.
Department of Mathematics and Applied Mathematics, Virginia Commonwealth University, Richmond, VA, United States of America.
PeerJ. 2024 Feb 7;12:e16869. doi: 10.7717/peerj.16869. eCollection 2024.
Human schistosomiasis is a chronic and debilitating neglected tropical disease caused by parasitic worms of the genus Schistosoma. It is endemic in many countries in sub-Saharan Africa. Although there is currently no vaccine available, vaccines are in development. In this paper, we extend a simple compartmental model of schistosomiasis transmission by incorporating the vaccination option. Unlike previous models of schistosomiasis transmission that focus on control and treatment at the population level, our model focuses on incorporating human behavior and voluntary individual vaccination. We identify vaccination rates needed to achieve herd immunity as well as optimal voluntary vaccination rates. We demonstrate that the prevalence remains too high (higher than 1%) unless the vaccination costs are sufficiently low. Thus, we can conclude that voluntary vaccination (with or without mass drug administration) may not be sufficient to eliminate schistosomiasis as a public health concern. The cost of the vaccine (relative to the cost of schistosomiasis infection) is the most important factor determining whether voluntary vaccination can yield elimination of schistosomiasis. When the cost is low, the optimal voluntary vaccination rate is high enough that the prevalence of schistosomiasis declines under 1%. Once the vaccine becomes available for public use, it will be crucial to ensure that the individuals have as cheap an access to the vaccine as possible.
人类血吸虫病是一种由血吸虫属寄生虫引起的慢性衰弱性被忽视热带病。它在撒哈拉以南非洲的许多国家流行。尽管目前尚无可用疫苗,但疫苗正在研发中。在本文中,我们通过纳入疫苗接种选项扩展了一个简单的血吸虫病传播房室模型。与以往侧重于人群层面控制和治疗的血吸虫病传播模型不同,我们的模型侧重于纳入人类行为和自愿个体疫苗接种。我们确定了实现群体免疫所需的疫苗接种率以及最佳自愿疫苗接种率。我们证明,除非疫苗接种成本足够低,否则患病率仍会过高(高于1%)。因此,我们可以得出结论,自愿疫苗接种(无论是否进行大规模药物治疗)可能不足以消除作为公共卫生问题的血吸虫病。疫苗成本(相对于血吸虫病感染成本)是决定自愿疫苗接种能否实现血吸虫病消除的最重要因素。当成本较低时,最佳自愿疫苗接种率足够高,以至于血吸虫病患病率降至1%以下。一旦疫苗可供公众使用,确保个人能够尽可能廉价地获取疫苗将至关重要。